Vanguard Personalized Indexing Management LLC Purchases 36,933 Shares of Pfizer Inc. $PFE

Vanguard Personalized Indexing Management LLC raised its position in Pfizer Inc. (NYSE:PFE) by 7.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 541,379 shares of the biopharmaceutical company’s stock after purchasing an additional 36,933 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Pfizer were worth $13,797,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Fiduciary Alliance LLC raised its stake in shares of Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares in the last quarter. Vista Investment Partners LLC grew its stake in Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. increased its holdings in Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 47,319 shares during the period. Fort Washington Investment Advisors Inc. OH raised its position in Pfizer by 11.2% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company’s stock valued at $48,225,000 after purchasing an additional 190,946 shares in the last quarter. Finally, Ossiam lifted its holdings in shares of Pfizer by 71.2% in the 2nd quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock worth $136,970,000 after buying an additional 2,349,058 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Finally, Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $27.88.

Pfizer Trading Down 1.7%

Shares of Pfizer stock opened at $25.65 on Monday. The firm’s 50 day simple moving average is $25.40 and its two-hundred day simple moving average is $25.00. The firm has a market capitalization of $145.82 billion, a price-to-earnings ratio of 14.91 and a beta of 0.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.